Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.

The voluntary withdrawal of the license for the UK major's COVID-19 vaccine is due to a surplus of available updated jabs from other companies that target new variants and is not connected to the mis- and disinformation being peddled on the internet and elsewhere on very rare adverse events.

The FTC is intensifying its crackdown on pharmaceutical companies' misuse of patent listings as industry seeks clearer guidelines.

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve access to lifesaving therapies. Payers and politicians must be persuaded to loosen their purse strings – and open their minds.